Haizheng Pharmaceutical (600267.SH): Bedaquiline fumarate tablets obtained drug registration certificate

Zhitongcaijing · 1d ago

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for bedaquiline fumarate tablets approved and issued by the State Drug Administration. Bedaquiline fumarate tablets are a Class B drug in the medical insurance list. It is a diarylquinoline antimycobacterial drug. As part of combination treatment, it is suitable for the treatment of at least adults and adolescents (12 to <18 years old and body weight ≥30 kg) caused by Mycobacterium tuberculosis resistant to rifampicin and isoniazid.